LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting
본 제품은 LMO 제품으로, 고객 분께서 LMO 신고 시스템을 통해 직접 수입 신고를 진행해주셔야 합니다. 자세히보기
Product Image
인용 및 참조 문헌 (1)
Invitrogen™

LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting

Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control자세히 알아보기
Have Questions?
카탈로그 번호수량
A32062100 μL
카탈로그 번호 A32062
제품 가격(KRW)
598,000
온라인 행사
Ends: 31-Dec-2025
664,000
할인액 66,000 (10%)
Each
카트에 추가하기
수량:
100 μL
제품 가격(KRW)
598,000
온라인 행사
Ends: 31-Dec-2025
664,000
할인액 66,000 (10%)
Each
카트에 추가하기
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome.
For Research Use Only. Not for use in diagnostic procedures.
사양
제어 유형Non-targeting negative control
배달 유형Lentiviral
용도(애플리케이션)CRISPR gene knockout
제품라인LentiArray
제품 유형CRISPR Negative Control Lentivirus
수량100 μL
배송 조건Dry Ice
프로모터U6
종Human
Transfection TechniqueLentiviral transduction
Unit SizeEach
구성 및 보관
1 x 100 μL. Store at -68 to -85°C.

인용 및 참조 문헌 (1)

인용 및 참조 문헌
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More